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Abstract
Medulloblastoma (MB) is the most common malignant brain tumour in children and is subdivided into four sub-
groups: WNT, SHH, Group 3, and Group 4. These molecular subgroups differ in their metastasis patterns and related
prognosis rates. Conventional 2D cell culture methods fail to recapitulate these clinical differences. Realistic 3D
models of the cerebellum are therefore necessary to investigate subgroup-specific functional differences and their
role in metastasis and chemoresistance. A major component of the brain extracellular matrix (ECM) is the glycosami-
noglycan hyaluronan. MB cell lines encapsulated in hyaluronan hydrogels grew as tumour nodules, with Group 3 and
Group 4 cell lines displaying clinically characteristic laminar metastatic patterns and levels of chemoresistance. The
glycoproteins, laminin and vitronectin, were identified as subgroup-specific, tumour-secreted ECM factors. Gels of
higher complexity, formed by incorporation of laminin or vitronectin, revealed subgroup-specific adhesion and
growth patterns closely mimicking clinical phenotypes. ECM subtypes, defined by relative levels of laminin and vitro-
nectin expression in patient tissue microarrays and gene expression data sets, were able to identify novel high-risk
MB patient subgroups and predict overall survival. Our hyaluronan model system has therefore allowed us to func-
tionally characterize the interaction between different MB subtypes and their environment. It highlights the prog-
nostic and pathological role of specific ECM factors and enables preclinical development of subgroup-specific
therapies.
© 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great
Britain and Ireland.
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Introduction
Medulloblastoma (MB) is the most common malignant
brain tumour in children and is subdivided into four sub-
groups: WNT, sonic hedgehog (SHH), Group 3, and
Group 4. These molecular subgroups are characterized
by different metastasis patterns and related prognosis
rates [1–4]. During the past decade, theseMB subgroups
have been defined based on gene expression, and further
refined with the help of additional DNA methylation
data, resulting in four major MB subgroups with addi-
tional subtypes [1,2,5,6]. The introduction of MB sub-
groups added a new classification tool and facilitated
the differentiation of low-, average-, high-, and very
high-risk patients [7,8] as an indicator of outcome.
Metastatic dissemination is the most powerful predic-
tor of poor outcome across all MB subgroups [9–11].
Recently, Zapotocky et al observed and quantified char-
acteristic tumour phenotypes according to the MB sub-
groups as radiological differences in primary tumour
sizes and metastatic phenotypes [12,13]. In metastatic
MB, Group 3 primary tumours are usually significantly
smaller than SHH or Group 4 tumours; hence they
hypothesized that an earlier dissemination event might
be a characteristic of Group 3 tumours. Importantly, they
also categorized the type of metastasis and found that
Group 3 tumours predominantly spread as nodules and
a thin laminar coating (laminar phenotype). In contrast,
SHH tumours predominantly metastasize as nodules
only (nodular phenotype), while Group 4 tumours can
metastasize as nodules as well as a laminar coating
[13]. The majority of genomic and transcriptional alter-
ations that have been identified to date have, however,
not been linked to signalling aberrations that could
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explain leptomeningeal spread or be targeted in meta-
static MB subgroups [14].
Based on the above observations, we hypothesized
that interaction with the surrounding extracellular
matrix (ECM) might differ between the MB sub-
groups, thus explaining subgroup-specific adhesion,
invasion, and growth patterns. The radiological find-
ings suggest that the most significant differences in
ECM interaction and remodelling might be expected
between Group 3 and SHH tumours, while Group
4 tumours would be characterized by an intermediate
phenotype. Investigation of subgroup-specific ECM
interactions required a modifiable but realistic in vitro
model system that allows long-term growth and remo-
delling of the local extracellular matrix by encapsu-
lated tumour cells. The brain microenvironment is
unique in its composition and characteristics [15–17].
In contrast to the ECM environment in many other
organs of the human body, fibrous proteins such as col-
lagens are in low abundance, whereas the glycosami-
noglycan hyaluronan (HA) and HA-proteoglycan
superstructures are major components of the brain
ECM [17,18]. No in vitro system currently exists that
addresses the unique composition and characteristics
of the brain microenvironment.
Here, we developed a 3D cell culture model that
allows investigation of the different metastatic tumour
phenotypes observed in medulloblastoma subtypes. We
used a 3D HA hydrogel model to show that the specific
ECM composition as well as active ECM remodelling
by MB tumour cells alters the adhesion, invasion, and
growth characteristics of the tumour. Our model retains
cell–HA interactions, which are potentially a crucial part
of the brain tumour–matrix interface [19,20]. Based on
the RNA and protein expression levels of MB
subgroup-specific ECM components and receptors, we
identified the glycoproteins laminin and vitronectin as
functional markers that can act as predictors of a laminar
or nodular phenotype. The resultant ECM subtypes cor-
related with overall patient survival and highlight MB
subgroup differences in ECM interaction.
Materials and methods
HA hydrogel preparation
Hyaluronan cross-linked hydrogels were prepared
according to the manufacturer’s recommendations
(HyStem; BioTime Inc, Alameda, CA, USA) using par-
ticular hyaluronan (1%) and Extralink (2% PEGDA)
concentrations. Further details can be found in Supple-
mentary materials and methods.
Cell viability assay
For cell viability assays, Prestoblue reagent (Thermo
Fisher, Waltham, MA, USA) was used according to the
manufacturer’s instructions and fluorescence intensity
was measured after 40 min incubation time using a
microplate reader (FLOUstar Omega; BMG Labtech,
Ortenberg, Germany). For 3D hydrogel viability assays,
all gels were washed four times with HBSS buffer
(Thermo Fisher) before fresh medium was added to each
well. Cell viability within each gel was measured weekly
after drug or vehicle treatment.
Vincristine drug treatment in 2D and 3D
Vincristine (VCR) (S1241; Selleckchem, Munich,
Germany; 825 Da) was added to the cell culture medium
at three different concentration of VCR dissolved in
DMSO (Sigma-Aldrich, St Louis, MO, USA). The
VCR concentrations chosen were the IC50 of a single
VCR dosage (5 nM) as well as the two-fold (10 nM) and
ten-fold IC50 (50 nM) as defined in spheroid cultures.
DMSO was used as a vehicle control. For the 2D exper-
iment, VCR was renewed 24 h after the first treatment.
For the 3D gel experiment, 3-week-old hydrogels were
treated with VCR and VCR renewal was performed
24, 72, and 144 h after the first dose. In order to assess
the cell’s recovery potential, all gels were washed and
covered with fresh, drug-free medium 1 week after the
final VCR treatment and monitored for a further 4 weeks
(total experiment time: 8 weeks).
Statistics
Results are shown as mean  SEM of the indicated
number of independent experiments. The statistical sig-
nificance of differences of group results was compared
using one- or two-way analysis of variance (ANOVA)
with a Dunnett’s post hoc test to correct for multiple
comparisons as indicated. Normal distribution and
homogeneity of variance were tested using the
Kolmogorov–Smirnov test and the F-test. For nonpara-
metric group results, the Kruskal–Wallis test with
Dunn’s post hoc test was performed. Significance levels
are indicated as *p < 0.05, **p < 0.01, and
***p < 0.001. All statistical analyses and plots were car-
ried out using GraphPad Prism 7.05 (GraphPad Software
Inc, La Jolla, CA, USA) unless stated otherwise. The
number of biological samples, corresponding statistical
test, and significance levels are indicated in each figure
legend. Kaplan–Meier survival data analysis was per-
formed using the R2: Genomics Analysis and Visualiza-
tion Platform (http://r2.amc.nl) and statistical
significance was tested using the log-rank test as
described by Bewick et al [21].
Detailed methods for Medulloblastoma cell lines,
culturing, and reagents; HA hydrogel preparation,
long-term cell culture, and quantification of invasion;
Etoposide drug treatment in 3D; Western blotting;
RNA isolation and RNA sequencing; RNA sequence
data analysis; Microarray data analysis; Combined data
analysis; Immunohistochemistry of HA hydrogels and
tissue microarrays; and ECM protein enrichment
analysis, ECM subtype definition, and overall survival
analysis are presented in Supplementary materials and
methods.
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Results
Long-term 3D hydrogel culture recapitulates MB
subgroup-specific invasion patterns and
chemotherapy resistance
In our study we used six different medulloblastoma cell
lines representing the SHH, Group 3, and Group
4 medulloblastoma subgroups as validated by RNA
sequencing (supplementary material, Figure S1). To
study growth differences between MB subgroups and
the role of the ECM, we compared long-term growth of
MB cell lines encapsulated in hyaluronan hydrogels with
conventional 2D cell culture. In 2D, cell growth does not
reflect the clinical phenotype or aggressiveness of the
particular subgroup (supplementary material,
Figure S2A). For example, Group 4 cell lines show the
slowest growth in vitro (supplementary material,
Figure S2A: CHLA-01/01R-MED), although Group
4 MB is characterized by high metastasis rates and inter-
mediate to poor prognosis concordant with high tumour
aggressiveness compared with the less aggressive p53
wild-type SHH subtype (ONS76).
We hypothesized that a more realistic brain-like envi-
ronment would uncover MB subgroup-specific pheno-
types and allow us to investigate functionally relevant
interactions between the tumour cells and the ECM.
Since the brain ECM is relatively rich in glycosamino-
glycans compared to fibrous proteins such as collagens,
we decided to use modifiable HA hydrogels as a simple
3D model. MB cell lines were encapsulated as single
cells or small clusters (Group 4) in HA hydrogels and
their growth was monitored for up to 60 days (supple-
mentary material, Figure S2B–F). The HA hydrogels
supported the growth of nodules containing actively
dividing cells for at least 60 days.
Radiological studies [13] have shown that metastasis
patterns differ between the MB subgroups. While SHH
tumours are predominantly nodular, the more aggressive
Group 3 tumours metastasize predominantly in a laminar
phenotype which is defined by the occurrence of nodules
and additional thin laminar coatings (Figure 1A). Group
4 tumours are intermediate, with either a laminar or a
nodular phenotype (Figure 1A). Long-term growth of
MB cell lines as nodules inside HA hydrogels also
reveals subgroup-specific invasion patterns and time
courses. Since the gels are prepared as ‘sandwich layers’
(see the Materials and methods section), a defined cell-
free gel volume has to be crossed to reach the gel–media
interface or the well bottom. Some cell lines were found
to invade through the gels and form a monolayer on the
bottom or on the gel surface in addition to the nodules in
the centre. The occurrence and time point of these inva-
sion events differ between the MB subgroups
(Figure 1B). While neither SHH cell line invaded
through the HA hydrogels (Figure 1B,C), Group 3 and
Group 4 cell lines frequently invaded after 2–3 weeks
and formed the additional laminar coating (Figure 1B,
D,E). The cell line-specific invasion in the HA hydrogels
correlates well with the described radiological
observations and underlines the benefits of the 3D
hydrogel model to demonstrate subgroup-specific intrin-
sic invasion capacities.
We compared the response of MB nodules and cells
grown in 2D in vitro assays with a chemotherapeutic
agent. Vincristine (VCR) is commonly used for MB
treatment, for example as part of the Packer protocol
[22] but also in ongoing trials (NCT01878617,
NCT02724579, NCT02066220), and is usually given
in repeated doses. For the 2D experiments, MB cell lines
were treated twice within 3 days with one of three differ-
ent VCR concentrations, and cell viability was moni-
tored. All MB cell lines were killed with the repeated
VCR dosage regardless of the concentration applied
(Figure 2A–C). For the 3D hydrogel experiment, the cell
lines were embedded inside the gels and allowed to form
and establish nodules for 3 weeks before treatment. Over
the following week, four treatments of VCR were given,
and nodule viability was monitored for a further
4 weeks. The IC50 VCR concentration did not signifi-
cantly reduce cell viability of the SHH cell line but the
two-fold and ten-fold VCR IC50 were effective
(Figure 2D). In contrast, the highly aggressive Group
3 and Group 4 cell lines remained almost unaffected by
the repeated treatment with one- and two-fold VCR
IC50 concentrations. Only the ten-fold VCR IC50 signif-
icantly reduced cell viability of the Group 3 cell line,
although it still had no effect on the Group 4 cell line
(Figure 2E,F). These subgroup-specific drug responses
could not have been predicted from the 2D in vitro data
but are in line with clinical observations demonstrating
the efficacy of chemotherapy for WNT/SHH subgroups
but not Group 3/4 MB patients [23].
To further evaluate the subgroup-specific response to
chemotherapy, we treated 3-week-old hydrogels with
etoposide (ETO; four treatments in 1 week) and moni-
tored nodular growth for several weeks (supplementary
material, Figure S3A,B). While the viability of the
SHH cell line decreased depending on the ETO dosage
(supplementary material, Figure S3A), the Group 3 nod-
ules remained unaffected by 0.5 μM and 1 μM ETO treat-
ments (supplementary material, Figure S3B). Only the
ten-fold ETO IC50 effectively decreased Group 3 cell
viability.
Taken together, our data show that the 3D HA hydro-
gel is a relevant model for MB that can recapitulate clin-
ically distinct characteristics of MB subgroups and
therefore could be used to investigate specific differ-
ences in MB subgroup–ECM interactions.
The glycoproteins laminin and vitronectin identify
MB ECM subgroups
Next, we aimed to identify subgroup-specific ECM com-
ponents. To identify important and specific ECM
markers for the MB subgroups, we used the largest pub-
licly available MB gene expression data set [6]. We ana-
lysed ECM-associated genes with highest expression in
Group 3, intermediate expression in Group 4, and lowest
expression in SHH tumours, and vice versa (Materials
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and methods section and supplementary material,
Figure S4). Vitronectin (VTN) was the most highly
expressed gene in Group 3 tumours relative to SHH
and showed intermediate expression in Group 4 (supple-
mentary material, Figures S4A–D and S5A). Seven
ECM component encoding genes with the opposite
Figure 1 Legend on next page.
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Figure 1. Clinically relevant subgroup-specific invasion patterns of Group 3 and Group 4 MB cell lines can be observed after 2–3 weeks of
long-term growth in the HA hydrogels. (A) Metastatic character differs between MB subgroups according to Zapotocky et al [13]. Group
3 tumours predominantly metastasize as a laminar coating, while SHH tumours predominately metastasize as nodules and Group 4 tumours
have an intermediate phenotype. (B) During long-term 3D culture, Group 3 and Group 4 cell lines frequently invade through the hydrogel and
grow as an additional monolayer either on the surface or on the bottom of the well, while this was never observed using SHH cell lines
(n = 34; DAOY, D458; n = 24 HD-MB03; n = 22; ONS76, CHLA-01-MED; n = 20 CHLA-01R-MED). Representative images of the invasive
behaviour over time are shown for the SHH line ONS76 (C), the Group 3 cell line HD-MB03 (D), and the Group 4 cell line CHLA-01-MED
(E) (scale bar = 100 μm). Images are of the areas indicated in the schematic, with the insets representing different focal planes to delineate
nodular and laminar growth phenotypes.
Figure 2. Vincristine (VCR) treatment kills MB cell lines effectively in 2D culture, while Group 3 nodules growing in HA hydrogels display
strong resistance comparable to clinical observations. The VCR concentrations chosen were the IC50 of a single VCR dosage (5 nM) as well
as the two-fold (10 nM) and ten-fold IC50 (50 nM). In 2D cell culture, 5 nM, 10 nM, and 50 nM VCR significantly reduces the viability of
(A) the SHH cell line ONS76, (B) the Group 3 cell line HD-MB03, and (C) the Group 4 cell line CHLA-01-MED (mean  SEM, n = 3 ONS76;
n = 4 HD-MB03; n = 3 CHLA-01-MED; two-way ANOVA and Dunnett’s post hoc test). After 3 weeks of growth inside the HA hydrogels,
(D) the SHH cell line ONS76, (E) the Group 3 cell line HD-MB03, and (F) the Group 4 cell line CHLA-01-MED were treated four times with
either 5 nM, 10 nM or 50 nM VCR or vehicle during 1 week and cell viability was monitored for the following 4 weeks in the absence of
drug/vehicle. While 10 nM and 50 nM VCR significantly reduce cell viability in the SHH cell line, only 50 nM VCR significantly affected Group
3 cell viability. The Group 4 cell line was completely resistant to VCR in 3D (mean  SEM, n = 3; two-way ANOVA and Dunnett’s post hoc
test). *p < 0.05, **p < 0.01, and ***p < 0.001.
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expression pattern, i.e. highest expression in SHH
tumours, were identified in the same way (Materials
and methods section and supplementary material,
Figure S4A–C,E). These included LAMA1 (encoding
the α subunit of laminin 111), ITGA6, and ITGA7 (sup-
plementary material, Figures S4E and S5B). Laminins
are heterotrimeric proteins that consist of α, β, and γ sub-
units; brain basement membranes include laminin iso-
forms 111 and the homologous isoform 211, in
contrast to the endothelial laminins 411 and 511 [24].
We therefore compared additionally the gene expression
of β and γ subunits. We found α2 and γ1 subunits to be
significantly higher-expressed in SHH tumours, whereas
Group 3 and Group 4 tumours expressed equivalent
levels (supplementary material, Figure S4A–C). In addi-
tion, ITGA6 is relevant for binding laminin-111 and
-211, while ITGA7 is more relevant for laminin-211,
further supporting the role of laminin-111 and -211 in
SHH tumours.
We concluded that laminin-111/211 and vitronec-
tin can be used as initial candidates for investigating
MB subgroup–specific ECM interactions. It is, how-
ever, well described that matrix deposition/manipula-
tion cannot necessarily be predicted from gene
expression data [25]. Therefore, we stained MB tissue
microarray sections for proteins of the identified gene
markers (TMA; supplementary material, Table S1).
Interestingly, we identified different combinations
of laminin-111/211 and vitronectin expression pat-
terns in the MB subgroups (Figure 3). In SHH
tumours, we found LAMhigh/VTNlow samples with
high laminin-111/211 expression but low vitronectin
protein levels (Figure 3A,B) as well as samples with
high vitronectin but low LAM-111/211 (Figure 3A;
supplementary material, Figure S6A). For Group
3 and Group 4 tumours, as well as the LAMhigh/
VTNlow and LAMlow/VTNhigh pattern (Figure 3C,D;
supplementary material, Figure S6B,D,E), two addi-
tional patterns of equivalent low or high expression
of both markers were identified (Figure 3E,F; supple-
mentary material, Figure S6C). In the majority of
cases, however, high expression of both glycopro-
teins, laminin-111/211 and vitronectin, seemed to be
mutually exclusive, suggesting opposing roles of
laminin and vitronectin, which is in agreement with
the gene expression data. Indeed, these ECM patterns
defined by laminin and vitronectin protein expression
on patient’s TMAs could also be seen at the gene
expression level using the data set from Cavalli et al
[6] (supplementary material, Figure S7). Laminin
and vitronectin gene expression in the Cavalli data
set (supplementary material, Figures S4, S5, and S7)
and protein expression in the TMAs (Figure 3) show
that there are different combinations of LAM/VTN
(high/low, low/low, high/high, low/high) that present
to varying degrees in the MB subgroups, indicating
that the ECM is a key candidate for the different
tumour phenotypes regarding adhesion, invasion,
and migration.
Laminin and vitronectin incorporation into
hyaluronan gels induces nodular or laminar growth
patterns; laminin and vitronectin are also actively
secreted by the cell lines
In order to test the influence of laminin and vitronectin
on the MB metastatic growth phenotype, we created
composite hydrogels, by combining laminin or vitronec-
tin with HA hydrogel, and assessed the behaviour of
cells when seeded on top of the gels (mimicking the lep-
tomeningeal surface) (Figure 4; supplementary material,
Figures S8–S10). The growth pattern of both SHH cell
lines differed markedly on the different matrix composi-
tions and was distinct from the behaviour observed for
Group 3 and Group 4 cell lines. The SHH cell lines
(DAOY, ONS76) formed one loosely attached central
spheroid-like structure when seeded on pure HA gels,
while a laminin-containing HA hydrogel induced the
growth of multiple fast-growing nodules. In contrast,
vitronectin-enriched HA hydrogels completely abol-
ished the nodular growth pattern of SHH cell lines and
supported growth as a flat, laminar monolayer
(Figure 4, left columns). In comparison to the SHH cell
lines, Group 3 (HD-MB03, D458) and Group
4 (CHLA-01-MED, CHLA-01R-MED) representative
cell lines were able to grow and cover the whole gel area
as a monolayer on all three matrix compositions
(Figure 4, central and right columns). On pure HA gels,
Group 4 cell lines attached across the whole gel area as
single cells and clusters, while Group 3 cell lines grew
as a central flat monolayer. The laminin-containing HA
hydrogel supported initial adherence of single cells that
formed clusters and filled the gaps between each other
over time with a laminar coating. In comparison to lam-
inin, vitronectin-supplemented HA hydrogels initiated
the flat monolayer growth of Group 3 cell lines. Impor-
tantly, vitronectin had a similar effect to laminin on
Group 4 cell lines by supporting growth and adherence
of single cells, cell clusters, and loose nodules. Our
hydrogel model therefore confirms the different roles
of laminin and vitronectin in drivingMB growth patterns
and highlights MB subgroup-specific adherence and
growth differences.
Since we already observed MB subgroup-specific
invasion patterns and chemotherapy responses after
long-term growth in HA hydrogels, we hypothesized
that these differences might also reflect a cell line-
specific ECM deposition. To test for the presence of
secreted laminin and vitronectin, we processed pure
HA hydrogels after 3 weeks of cell encapsulation for
immunohistochemistry and stained the nodules for
CD44, laminin, and vitronectin (Figure 5). The HA
receptor CD44 has been linked to brain tumour progres-
sion;[26–28] hence we chose CD44 as a marker for our
MB cell–HA interaction. All cell lines expressed CD44
throughout the whole nodule volume. Although the cell
lines had been seeded in pure HA hydrogels without any
other ECM factor addition, we found laminin and vitro-
nectin present in the MB cell line nodules. Laminin
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expression was low in the nodule derived from the pri-
mary Group 4 cell line, while it was diffusely expressed
in the nodule derived from the Group 4 relapse, as well
as in Group 3 cell line-derived nodules. Interestingly,
laminin expression followed a very distinct pattern in
SHH nodules. While laminin was diffusely expressed
in the central nodule core, it also formed a ring-like
structure that separated the central core from the outer
nodule zone, suggesting a structural role of laminin in
SHH nodules. Vitronectin was either not present or only
secreted at the outer edge of SHH nodules. In contrast,
diffuse vitronectin staining was found throughout the
whole volume of Group 3 nodules, whilst in Group
4 nodules, expression was initially located at the outer
edge of the primary, becoming more diffuse at relapse.
To summarize, ECM factors that have been identified
fromMBpatient’s RNA and protein data were expressed
and secreted by MB cell lines growing as nodules inside
our HA hydrogel model, confirming the biological
relevance of our realistic 3D models. Therefore, differ-
ences in ECM factor expression level and distribution
throughout the nodule might contribute to the observed
functional differences in invasion and chemoresistance
of the MB subgroups (Figures 1 and 2).
Identified ECM subtypes predict patient’s overall
survival and uncover MB subgroup differences
Having provided evidence that laminin and vitronectin
can alter the growth and adhesion patterns of MB sub-
groups and that both are actively secreted by the tumour
cells, survival analysis based on ECM subtypes was then
performed using Cavalli et al’s data set [6] (Figure 6 and
supplementary material, Figure S11). In the SHH sub-
group, the ‘LAMhigh/VTNlow’ subtype correlated with
a very good prognosis, while patients with low expres-
sion of laminin and vitronectin had a significantly worse
survival prognosis (Figure 6A; p = 0.003). In contrast,
Figure 3. Protein expression of laminin and vitronectin in patients’ TMAs defines relevant ECM subgroups in MB. (A) IHC staining of SHH
tumours (n = 11) reveals two main ECM patterns (LAMhigh/VTNlowand LAMlow/VTNhigh). (B) An example of a ‘LAMhigh/VTNlow’ SHH tumour
with low vitronectin positivity. (C) In Group 3 tumours (n = 6), the predominant expression pattern is equivalent expression of laminin
and vitronectin next to the ‘LAMlow/VTNhigh’ pattern. (D) An example of a ‘LAMlow/VTNhigh’ expressing tumour shows moderate to high stain-
ing for vitronectin and low laminin expression. (E) For MB Group 4 (n = 25), ‘LAMhigh/VTNlow’ and ‘LAMlow/VTNhigh’ groups are more common
than the equivalent expression pattern of laminin and vitronectin. (F) An example for a ‘LAMhigh/VTNhigh’ Group 4 tumour is shown (scale
bar = 100 μm). Examples for the other expression patterns are shown in supplementary material, Figure S5 and clinical information is listed
in supplementary material, Table S1.
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Figure 4 Legend on next page.
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Figure 4. Only Group 3 and Group 4 MB cell lines show laminar growth patterns on HA gels, while SHH cell lines are characterized by nodular
growth that can only be altered by vitronectin. MB cell lines representing the different subgroups were seeded on top of pure HA hydrogels or
on hydrogels supplemented with either laminin or vitronectin. Growth patterns were monitored over time (number in the bottom right corner
equals day of growth). All Group 3 and Group 4 cell lines grow as relatively even laminar monolayers on all three different hydrogels and can
cover the whole area within a few weeks. In contrast, SHH cell lines struggle to adhere on pure HA and form a single central spheroid-like
structure instead over time. On laminin-supplemented HA hydrogels, these cells adhere and form multiple nodules over time. In contrast,
the vitronectin-supplemented hydrogels provide the only surface where SHH MB cell lines grow as a thin laminar monolayer (scale
bar = 100 μm). The complete time course for all cell lines can be found in supplementary material, Figures S8–S10.
Figure 5.MB tumour nodules grown in pure HA gels express CD44 and secrete the identified ECM components laminin and vitronectin (VTN).
MB cell lines representing the different subgroups were grown inside HA hydrogels for 3 weeks, fixed, embedded in paraffin, and stained for
CD44, laminin-111/211, and vitronectin. All cell lines expressed high levels of the HA receptor CD44 (left panel). In contrast, laminin staining
was stronger in the relapse than in the primary Group 4 cell line (middle panel). Interestingly, both Group 3 cell lines show diffuse laminin
staining, while laminin expression follows a structural pattern in both SHH cell lines. In DAOY and ONS76 nodules, diffuse laminin staining
can be found in the core area, while a defined laminin ring separates the central area from the outer ring. Vitronectin staining (right panel)
was mainly found at the outer ring of SHH, whereas vitronectin was diffusely expressed throughout Group 3 nodules and the relapse Group 4
nodule (scale bar = 100 μm).
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Figure 6. ECM subgroups that are defined by the expression patterns of laminin-111/211 and vitronectin (VTN) are clinically relevant and
predict patient’s overall survival (OS) in a subgroup-specific manner. ECM subgroups have been assigned based on the expression level of
LAMA1/LAMA2 and VTR for every SHH, Group 3, and Group 4 patient of the gene expression dataset from Cavalli et al [6] (groups with survival
data: ‘LAMhigh/VTNlow’ n = 150; ‘LAMlow/VTNhigh’ n = 80; ‘LAMlow/VTNlow’ n = 244; ‘LAMhigh/VTNhigh’ n = 75). (A) In SHH MB, overall sur-
vival is good in the laminin group and significantly worse in patients with low expression of LAMA1/2 and vitronectin (n = 172, log-rank test,
p = 3.4e−03). (B) The laminin-dominated ECM subgroup makes up the majority of SHH cases. (C) In Group 3, patients with high vitronectin
have the worst overall survival (n = 113, log-rank test, p = 0.079). (D) In contrast to SHH, in Group 3 MB the ‘LAMhigh/VTNlow’ group is very
small, while the vitronectin-containing groups and the LAMlow/VTNlow group account for similar patient’s numbers. (E) In Group 4 MB, the
worst overall survival is associated with high LAMA1/2 expression (n = 264, log-rank test, p = 3.5e−03). (F) The largest ECM subtype of
Group 4 MB shows low expression of both ECM markers.
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low laminin expression but high levels of vitronectin
were associated with the worst overall survival in Group
3 patients (Figure 6B; p = 0.079). Interestingly, the five
Group 3 patients with high laminin and low vitronectin
expression had the best overall survival. While a high
laminin and low vitronectin expression defined patients
with good overall survival rates in the SHH and Group
3 cohorts, the opposite was true for Group 4, indicating
differences in the response to laminin between the MB
subgroups (Figure 6C; p = 0.004). In Group 4 patients,
the ‘LAMhigh/VTNlow’ subtype correlated with a very
poor prognosis, thus identifying a new high-risk Group
4 subtype. ECM subtypes can therefore be used to iden-
tify subgroup-specific high-risk patients.
Discussion
Metastatic dissemination remains the main challenge
and reason for therapy failure in MB [1,29]. Although
it is known that MB subgroups differ in metastatic fre-
quency, location, size, and morphology of metastases,
we still lack a deep mechanistic understanding of these
processes [4,13,30]. A favourable brain environment
that serves as a hospitable niche is a prerequisite for suc-
cessful metastatic growth [31,32]. There is an ongoing
discussion regarding whether subpopulations of cancer
cells already possess an intrinsic capacity to metastasize
or if the neural niche selection pressure causes some
cells to evolve and adapt to the new environment
[33–35]. Alternatively, a combination of these events,
i.e. bidirectional tumour–brain environment interac-
tions, might explain different morphologies and loca-
tions of brain metastases. The presence of MB
subgroup-specific nodular and laminar metastases might
therefore reflect subgroup-dependent biological differ-
ences that could present novel targets for therapeutic
intervention [13]. Models representing functional MB
subgroups would significantly advance our understand-
ing and ability to exploit these differences.
The 3D HA hydrogel model was capable of reprodu-
cing clinically relevant MB subgroup invasive pheno-
types. Our data suggest that long-term growth in a
realistic matrix allows the cells to alter their environment
and set up their specific favourable niche. As a conse-
quence, we observed highly metastatic and chemoresis-
tant behaviour of Group 3 and Group 4 cell lines and
pure nodular growth of SHH cell lines. Interestingly,
the long-term drug treatment model with vincristine as
well as etoposide revealed resistant cell populations.
Those cell populations remained viable post-treatment
and could therefore drive relapse. Our 3D hydrogel
model is therefore perfectly suited to studying long-term
drug response and potential resistance mechanisms, for
example by comparing cells before and after treatment.
Long-term hydrogel drug screening could therefore
become a valuable option to test efficiency and potential
resistance mechanisms of drug candidates that have been
identified using more high-throughput assays such as
spheroids or neurosphere cultures. Using the model also
provides the opportunity to identify and target novel fac-
tors involved in MB microenvironmental remodelling.
The glycoproteins laminin and vitronectin are
expressed by the cell lines in the HA hydrogel model,
correlating with patient’s samples at the RNA and pro-
tein level, supporting a potential role of laminin and
vitronectin in MB metastasis.
The expression and presence of laminin and vitronec-
tin not only predetermine the nodular or laminar growth
pattern but also define ECM subtypes. Based on these
ECM subtypes, laminin-expressing, high-risk Group
4 patients and vitronectin-expressing, high-risk Group
3 patients can be identified and important differences
between the MB subgroups are highlighted. Interest-
ingly, the high expression of laminin-111/211 is associ-
ated with very good overall survival in SHH and a small
proportion of Group 3 patients but with very poor sur-
vival in Group 4. This indicates that laminin can have
opposing roles depending on the particular cellular con-
text. In cancer and stem cell research, laminins have
been found to function as stem cell factors or inducers
of differentiation [36–41]. A better understanding of
the cell context-dependent functions of laminin and its
underlying signalling mechanisms will therefore be key
for future cancer studies.
For MB, we show that laminin supports the nodular
growth of SHH tumours and is a structural component
of SHH nodules. It also induces nodule-like cluster
formation of Group 4 cell lines but is not sufficient to
alter the Group 3 laminar growth morphology. We
hypothesize that SHH and Group 4 tumours share
some signalling similarities in response to laminin that
eventually induce the nodular phenotype. However,
further investigations will be required to understand
the obvious differences in laminin-induced cell signal-
ling between SHH and Group 4 tumours in order to
identify novel targets for the identified very high-risk
Group 4 subtype.
In contrast to laminin, we identified vitronectin as an
inducer of MB laminar growth. Vitronectin is a serum
protein with important functions in inflammation, tissue
repair, and homeostatic processes [42]. In glioma, vitro-
nectin is present not only in the serum but also in the
cerebrospinal fluid and induces glioma cell migration
in vitro [42]. Serum levels of vitronectin correlate with
glioma grade and predict outcome [43]. In our experi-
ments, vitronectin was only diffusely expressed in
Group 3 nodules and correlated with poor overall sur-
vival in Group 3 patients. Interestingly, vitronectin gene
and protein expression was low in SHH patients but
addition of vitronectin to the HA hydrogel induced lam-
inar growth of SHH cell lines. This suggests that respon-
siveness to ECM factors is similar between MB
subgroups but their intrinsic potential to secrete certain
ECM factors and therefore remodel their environment
differs. Future studies could test if the addition of single
ECM components also changes medulloblastomametas-
tasis in an in vivomodel using knockout cell lines for the
respective ECM factor.
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Our study highlights the potential of this research
area. The ability to model MB subgroup-dependent dif-
ferences in ECM interactions will not only enable us to
add a novel functional angle to the existing classification
schemes but will also increase our understanding of the
fundamental biological differences between MB sub-
groups and the potential for therapeutic intervention.
While conventional 2D cell culture only reveals pheno-
typical differences between the MB subgroups, 3D
hydrogel models also expose functional differences.
Acknowledgement
The research presented in this paper was supported by
The Stoneygate Trust (‘Career Catalyst Award’ awarded
to Dr Beth Coyle in 2016).
Author contributions statement
FL performed most of the experiments, with MA con-
tributing to specific experiments. AL analysed the RNA-
seq data. AMG, SST, IDK, MA and CLRM were in
involved in research design, manuscript writing, and
the final approval. FL and BC designed the research,
analysed and interpreted data, and wrote the manuscript.
Data availability statement
All data generated or analysed during this study are
included within the article. The RNA sequencing data
have been deposited in the ArrayExpress database at
EMBL-EBI under Annotare accession number E-
MTAB-9823 (http://www.ebi.ac.uk/arrayexpress).
References
1. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups
of medulloblastoma: the current consensus. Acta Neuropathol 2012;
123: 465–472.
2. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma com-
prises four distinct molecular variants. J Clin Oncol 2011; 29:
1408–1414.
3. Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma
have distinct developmental origins. Nature 2010; 468: 1095–1099.
4. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of
medulloblastoma: an international meta-analysis of transcriptome,
genetic aberrations, and clinical data of WNT, SHH, Group 3, and
Group 4 medulloblastomas. Acta Neuropathol 2012; 123: 473–484.
5. Sharma T, Schwalbe EC, Williamson D, et al. Second-generation
molecular subgrouping of medulloblastoma: an international meta-
analysis of Group 3 and Group 4 subtypes. Acta Neuropathol 2019;
138: 309–326.
6. Cavalli FMG, RemkeM, Rampasek L, et al. Intertumoral heterogene-
ity within medulloblastoma subgroups. Cancer Cell 2017; 31:
737–754.e6.
7. Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of
childhood medulloblastoma in the molecular era: the current consen-
sus. Acta Neuropathol 2016; 131: 821–831.
8. Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk strat-
ification groups in childhood medulloblastoma using combined clini-
cal, pathologic, and molecular variables. J Clin Oncol 2011; 29:
1400–1407.
9. vonHoff K, Hinkes B, Gerber NU, et al. Long-term outcome and clin-
ical prognostic factors in children with medulloblastoma treated in the
prospective randomised multicentre trial HIT’91. Eur J Cancer 2009;
45: 1209–1217.
10. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant
treatment, and residual tumor are prognostic factors for medulloblas-
toma in children: conclusions from the Children’s Cancer Group
921 randomized phase III study. J Clin Oncol 1999; 17: 832–845.
11. Holgado BL, Guerreiro Stucklin A, Garzia L, et al. Tailoring medul-
loblastoma treatment through genomics: making a change, one sub-
group at a time. Annu Rev Genomics Hum Genet 2017; 18: 143–166.
12. Dufour C, Beaugrand A, Pizer B, et al. Metastatic medulloblastoma in
childhood: Chang’s classification revisited. Int J Surg Oncol 2012;
2012: 245385.
13. Zapotocky M, Mata-Mbemba D, Sumerauer D, et al. Differential pat-
terns of metastatic dissemination across medulloblastoma subgroups.
J Neurosurg Pediatr 2018; 21: 145–152.
14. Coluccia D, Figuereido C, Isik S, et al. Medulloblastoma: tumor biol-
ogy and relevance to treatment and prognosis paradigm. Curr Neurol
Neurosci Rep 2016; 16: 43.
15. Zimmermann DR, Dours-Zimmermann MT. Extracellular matrix of
the central nervous system: from neglect to challenge.Histochem Cell
Biol 2008; 130: 635–653.
16. Dauth S, Grevesse T, Pantazopoulos H, et al. Extracellular matrix pro-
tein expression is brain region dependent. J Comp Neurol 2016; 524:
1309–1336.
17. Rauch U. Brain matrix: structure, turnover and necessity. Biochem
Soc Trans 2007; 35: 656–660.
18. Novak U, Kaye AH. Extracellular matrix and the brain: components
and function. J Clin Neurosci 2000; 7: 280–290.
19. Kim Y, Kumar S. CD44-mediated adhesion to hyaluronic acid con-
tributes to mechanosensing and invasive motility. Mol Cancer Res
2014; 12: 1416–1429.
20. Quail DF, Joyce JA. The microenvironmental landscape of brain
tumors. Cancer Cell 2017; 31: 326–341.
21. Bewick V, Cheek L, Ball J. Statistics review 12: survival analysis.
Crit Care 2004; 8: 389–394.
22. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal
radiation therapy followed by adjuvant chemotherapy for newly diag-
nosed average-risk medulloblastoma. J Clin Oncol 2006; 24:
4202–4208.
23. Zhang ZY,Xu J, Ren Y, et al. Medulloblastoma in China: clinicopath-
ologic analyses of SHH, WNT, and non-SHH/WNT molecular sub-
groups reveal different therapeutic responses to adjuvant
chemotherapy. PLoS One 2014; 9: e99490.
24. Yousif LF, Di Russo J, Sorokin L. Laminin isoforms in endothelial
and perivascular basement membranes. Cell Adh Migr 2013; 7:
101–110.
25. Cote AJ, McLeod CM, Farrell MJ, et al. Single-cell differences in
matrix gene expression do not predict matrix deposition.Nat Commun
2016; 7: 10865.
26. Shu C, Wang Q, Yan X, et al. Prognostic and microRNA profile anal-
ysis for CD44 positive expression pediatric posterior fossa ependy-
moma. Clin Transl Oncol 2018; 20: 1439–1447.
27. Nishikawa M, Inoue A, Ohnishi T, et al. Significance of glioma stem-
like cells in the tumor periphery that express high levels of CD44 in
tumor invasion, early progression, and poor prognosis in glioblas-
toma. Stem Cells Int 2018; 2018: 5387041.
12 F Linke et al
© 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd.
on behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org
J Pathol 2020; 00: 000–000
www.thejournalofpathology.com
28. BrownDV, Filiz G, Daniel PM, et al. Expression of CD133 and CD44
in glioblastoma stem cells correlates with cell proliferation, phenotype
stability and intratumor heterogeneity. PLoS One 2017; 12:
e0172791.
29. Fernandez-Teijeiro A, Betensky RA, Sturla LM, et al. Combining
gene expression profiles and clinical parameters for risk stratification
in medulloblastomas. J Clin Oncol 2004; 22: 994–998.
30. Northcott PA, Shih DJH, Peacock J, et al. Subgroup-specific struc-
tural variation across 1,000 medulloblastoma genomes. Nature
2012; 488: 49–56.
31. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for
brain tumor stem cells. Cancer Cell 2007; 11: 69–82.
32. Carbonell WS, Ansorga O, Sibson N, et al. The vascular basement
membrane as ‘soil’ in brain metastasis. PLoS One 2009; 4: e5857.
33. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells
within a malignant tumor. Science 1977; 197: 893–895.
34. Talmadge J, Wolman, Fidler I. Evidence for the clonal origin of spon-
taneous metastases. Science 1982; 217: 361–363.
35. Hoshide R, Jandial R. The role of the neural niche in brain metastasis.
Clin Exp Metastasis 2017; 34: 369–376.
36. Lathia JD, Li M, Hall PE, et al. Laminin alpha 2 enables glioblastoma
stem cell growth. Ann Neurol 2012; 72: 766–778.
37. De Arcangelis A, Lefebvre O, Méchine-Neuville A, et al. Overex-
pression of laminin α1 chain in colonic cancer cells induces an
increase in tumor growth. Int J Cancer 2001; 94: 44–53.
38. Qin Y, Rodin S, Simonson OE, et al. Laminins and cancer stem cells:
partners in crime? Semin Cancer Biol 2017; 45: 3–12.
39. Horejs C-M, Serio A, Purvis A, et al. Biologically-active laminin-111
fragment that modulates the epithelial-to-mesenchymal transition in
embryonic stem cells. Proc Natl Acad Sci U S A 2014; 111:
5908–5913.
40. Jin L, Feng T, Shih HP, et al. Colony-forming cells in the adult mouse
pancreas are expandable in Matrigel and form endocrine/acinar colo-
nies in laminin hydrogel. Proc Natl Acad Sci U S A 2013; 110:
3907–3912.
41. Yao Y, Chen Z-L, Norris EH, et al. Astrocytic laminin regulates peri-
cyte differentiation and maintains blood brain barrier integrity. Nat
Commun 2014; 5: 3413.
42. Leavesley DI, Kashyap AS, Croll T, et al. Vitronectin – master con-
troller or micromanager? IUBMB Life 2013; 65: 807–818.
43. Chen M-H, Lu C, Sun J, et al. Diagnostic and prognostic value of
serum vitronectin levels in human glioma. J Neurol Sci 2016; 371:
54–59.
44. Hynes WF, Doty NJ, Zarembinski TI, et al. Micropatterning of 3D
microenvironments for living biosensor applications. Biosensors
2014; 4: 28–44.
45. Vanderhooft JL, Alcoutlabi M, Magda JJ, et al. Rheological proper-
ties of cross-linked hyaluronan-gelatin hydrogels for tissue engineer-
ing. Macromol Biosci 2009; 9: 20–28.
46. Andrews S. FastQC: A Quality Control Tool for High Throughput
Sequence Data. [Accessed 7 October 2020]. Available from: http://
www.bioinformatics.babraham.ac.uk/projects/fastqc/
47. MartinM. Cutadapt removes adapter sequences from high-throughput
sequencing reads. EMBnet J 2011; 17: 10–12.
48. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal
RNA-seq aligner. Bioinformatics 2013; 29: 15–21.
49. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general
purpose program for assigning sequence reads to genomic features.
Bioinformatics 2014; 30: 923–930.
50. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor
package for differential expression analysis of digital gene expression
data. Bioinformatics 2010; 26: 139–140.
51. Affymetrix. Analysis Power Tools (APT). [Accessed 13 October
2020]. Available from: https://www.affymetrix.com/support/
developer/powertools/changelog/index.html
52. Thompson JA, Tan J, Greene CS. Cross-platform normalization of
microarray and RNA-seq data for machine learning applications.
PeerJ 2016; 4: e1621.
53. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microar-
ray expression data using empirical Bayes methods. Biostatistics
2007; 8: 118–127.
54. Pinto MP, Jacobsen BM, Horwitz KB. An immunohistochemical
method to study breast cancer cell subpopulations and their growth
regulation by hormones in three-dimensional cultures. Front Endocrinol
(Lausanne) 2011; 2: 15.
References 44–54 are cited only in the supplementary material.
SUPPLEMENTARY MATERIAL ONLINE
Supplementary materials and methods
Figure S1. Global gene expression of medulloblastoma cell lines correlates with clinical subgroup data
Figure S2. Comparison of MB cell line growth in 2D compared with long-term 3D culture
Figure S3. Etoposide (ETO) treatment kills the SHH MB cell line ONS76 effectively, while Group 3 nodules display strong resistance comparable to
clinical observations
Figure S4. Differential gene expression analysis of the data set from Cavalli et al [6] reveals SHH and Group 3 specific ECM markers
Figure S5.MB patients express subgroup-specific levels of laminin (LAM) and vitronectin (VTN) genes
Figure S6. Protein expression of laminin and vitronectin in TMAs
Figure S7. Analysis of the data set from Cavalli et al [6] reveals subgroup-specific differences in ECM protein expression patterns
Figure S8. Cell growth on pure HA hydrogels reveals remarkable differences between SHH cell lines and Group 3 and Group 4 cell lines
Figure S9. Cell growth on laminin-supplemented HA hydrogels revealed remarkable differences between SHH cell lines and Group 3 and Group 4 cell
lines
Figure S10. Cell growth on vitronectin-supplemented HA hydrogels revealed remarkable differences between SHH cell lines and Group 3 and Group
4 cell lines
Figure S11. ECM subtypes are composed of different MB subgroup proportions
Table S1. Clinicopathological characteristics of MB patients included in the TMAs
ECM medulloblastoma subtypes 13
© 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd.
on behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org
J Pathol 2020; 00: 000–000
www.thejournalofpathology.com
